[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hpv-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hpv-infection":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,43,0,25,[9,46,71,91,126,150,170,214,244,268,292,337,363,392,416,439,462,486,510,530,559,596,622,660,683],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100053378","effect-of-egcg-folic-acid-vitamin-b12-and-hyaluronic-acid-on-hpv-dna-integration-100053378",false,"NCT07697196","Effect of EGCG, Folic Acid, Vitamin B12 and Hyaluronic Acid on HPV DNA Integration","An Interventional Study Evaluating the Effect of Epigallocatechin Gallate (EGCG), Folic Acid (FA), Vitamin B12 (B12) and Hyaluronic Acid (HA) in Affecting the DNA Integration of Human Papilloma Virus (HPV) in Women With Persistent Infection","Inclusion Criteria:\n\n1. Age ≥ 25 years old\n2. Positive HPV DNA test with genotyping 9-24 months prior to Day 0\n3. Positive HPV DNA test with genotyping at Day 0\n4. Presence of an HPV-related cervical lesion within 5-24 months prior to Day 0. This lesion will be defined alternatively as:\n\n   1. Pap test: LSIL, ASC-US.\n   2. Colposcopic impression suggestive of a low-grade lesion.\n   3. Histologic report of a colposcopic biopsy consistent with a low-grade lesion.\n5. Previous HPV vaccination (latest dose at least 24 months earlier than Day 0)\n6. Patients able to accept and sign informed consent for the study\n7. Patients able to adhere to the proposed study protocol\n\nExclusion Criteria:\n\n1. High grade cervical lesions (HSIL)\n2. Ongoing pregnancy, evaluated through a rapid chromatographic immunoassay for qualitative detection of hCG in urine\n3. Ongoing breastfeeding\n4. Primary or secondary immunodepression due to pharmacological treatments\n5. No HPV vaccination\n6. Daily assumption of other products containing green tea\n7. Hypersensitivity or allergy to the substances contained in the supplement","FEMALE","25 Years",{"count":20,"type":21},42,"ESTIMATED","INTERVENTIONAL",[24],"NA","This interventional, single-center, open-label randomized clinical study evaluates the efficacy of an oral dietary supplement (Pervistop®) in women with persistent Human Papillomavirus (HPV) infection. The supplement is a combination of four natural molecules: Epigallocatechin gallate (EGCG), folic acid (FA), vitamin B12 (B12), and hyaluronic acid (HA).The primary objective is to describe the effect of this association on HPV DNA integration into the host genome by measuring the clearance rate of viral oncoproteins E6 and E7. A total of 42 women aged 25 or older with persistent HPV infection and low-grade cervical lesions will be randomized 1:1 into two groups. The treated group will receive one tablet of Pervistop® daily for six months, while the control group will follow standard clinical practice. The study aims to determine if this nutritional intervention can counteract viral persistence.",[27,28,29,30,31,32],"HPV Infection","HPV Integration","HPV Disease","HPV Genital Infection","HPV Persistence","Low Grade Squamous Intraepithelial Lesions of the Cervix","NOT_YET_RECRUITING","2026-07-06",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":21},"2026-07",{"date":41,"type":21},"2028-06",{"name":43,"class":44},"IRCCS San Raffaele","OTHER",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100532288","phase-2-assessing-administration-of-pbi-11-via-electroporation-for-the-treatment-of-patients-with-hpv1618-100532288","NCT06210854","Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16\u002F18+","Double-Blind Randomized Phase II Clinical Trial Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16\u002F18+ \u003CCIN2","Inclusion Criteria:\n\n* Negative for Intraepithelial Lesions (NEIL), Atypical Squamous Cells of Undetermined Significance (ASC-US), or Low-grade Squamous Intraepithelial Lesion (LSIL) determined by cervical cytology\n\nAND\n\n* HPV16 and\u002For 18+ by Roche Cobas 4800, Roche Linear Array HPV Genotyping test, or other FDA-approved HPV genotyping test (Co-infections with HPV types other than HPV16\u002F18 are permissible).\n* Age ≥ 18 years\n* Baseline Eastern Cooperative Oncology Group performance status of 0 or 1 at the time of enrollment.\n* Patients must have adequate organ function at the time of enrollment as defined by the following parameters:\n* White blood cell count ≥ 3,000 cells\u002FuL\n* Absolute lymphocyte number ≥ 500 cells\u002FuL\n* Absolute neutrophil count ≥ 1,500 cells\u002FuL\n* Platelets ≥ 90,000 cells\u002FuL\n* Hemoglobulin ≥ 9 g\u002FdL\n* Total bilirubin \\\u003C 3 X the institutional limit of normal\n* Aspartate Aminotransferase (AST) and Alanine Aminotransferase(ALT) \\\u003C 3 X the institutional limit of normal\n* Creatinine \\\u003C 2.5 X the institutional limit of normal\n* Women of child-bearing potential must agree to use long acting contraception (e.g. tubal ligation, intrauterine device or hormonal implant) or two forms of contraception (e.g. barrier method, oral contraceptives) prior to study entry and for 3 months after final vaccination.\n* Ability to understand and the willingness to sign a written informed consent document.\n* Able to adhere to the study visit schedule and other protocol requirements.\n\nExclusion Criteria:\n\n* Histologic evidence of CIN2, cervical intraepithelial neoplasia 3 (CIN3), adenocarcinoma in situ or malignancy.\n* Patients with a diagnosis of immunosuppression or active systemic use of immunosuppressive medications such as steroids.\n* Patients who are receiving any other investigational agents within 28 days prior to the first dose of study vaccine.\n* Patients with an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Patients with a history of systemic autoimmune disease such as multiple sclerosis or systemic lupus erythematosus (SLE), but exclusive of a history of thyroiditis, psoriasis, Sjogren's, or inflammatory bowel disease.\n* Patients who are pregnant or breast feeding or plan to become pregnant within 12 months of first study treatment.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to pBI-11 DNA vaccine.\n* Patient with active infection of, or receiving treatment for Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), or Hepatitis B Virus (HBV).\n* History of prior malignancy with disease free interval \\\u003C5 years; however, individuals with completely resected basal cell or squamous cell carcinoma of the skin within this interval may be enrolled.\n* Participants with metal implant(s) at the site of injection or any electronic stimulation device, such as cardiac demand pacemakers, automatic implantable cardiac defibrillator, nerve stimulators, or deep brain stimulators.\n* Participants with any chronic or active neurologic disorder, including seizures and epilepsy, excluding a single febrile seizure as a child or episode of seizure in pregnancy due to eclampsia.\n* Participants with syncopal episode within 12 months of screening, excluding fainting for a known and unrelated cause such as anemia which has been resolved.\n* Administration of immunoglobulins and\u002For any blood products within the 120 days preceding study entry or planned administration during the study period.\n* Participants with a skin-fold measurement of the cutaneous and subcutaneous tissue for all eligible injection sites (vastus lateralis muscles with intact lymph drainage) exceeds 50 mm.\n* Participants in whom the ability to observe possible local reactions at the injection site (lateralis region) is, in the opinion of the investigator, unacceptably obscured due to a physical condition or permanent body art.","18 Years",{"count":55,"type":21},48,[57],"PHASE2","This research is being done to test the safety and feasibility of an investigational DNA vaccine called pBI-11 and to find out what effects, if any, it has on women with persistent human papillomavirus 16 (HPV16+) and\u002For human papillomavirus (HPV18+) cervical infection.\n\nThe DNA vaccine is designed to promote an immune response to treat disease caused by HPV types 16 and 18, viruses that can cause cervical cancer. The pBI-11 DNA vaccine or a placebo will be administered intramuscularly using the TriGridTM Delivery System.",[27],"RECRUITING","2026-06-30",{"date":63,"type":37},"2026-07-01",{"date":65,"type":37},"2026-06-25",{"date":67,"type":21},"2029-05",{"name":69,"class":44},"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",2,{"id":72,"slug":73,"hasResults":12,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":84,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":45},"100538474","non-invasive-plasma-treatment-for-cervical-infections-targeting-high--and-low-risk-hpv-variants-100538474","NCT06291311","Non-Invasive Plasma Treatment for Cervical Infections: Targeting High- and Low-Risk HPV Variants","Treatment of Infections of the Cervix Uteri With High- and Low-risk Variants of the Human Papillomavirus Using Non-invasive Physical Plasma","Inclusion Criteria:\n\n* Inclusion criteria for NIPP treatment\n\n  * Age ≥ 18 years\n  * mRNA or DNA-based virus detection by smear (also external findings)\n  * Clearly visible transformation zone of the cervix and margins of the lesions corresponding to T1\u002FT2\n  * Written informed consent to participate in the study\n* Inclusion criteria for control group\n\n  * Age ≥ 18 years\n  * Swab-based mRNA or DNA-based virus detection (also external findings)\n  * Clearly visible transformation zone of the cervix corresponding to T1\u002FT2\n  * Written informed consent to participate in the study\n\nExclusion criteria:\n\nThe following exclusion criteria apply to both groups of patients (NIPP treatment and control group).\n\n* Transformation zone not fully visible\n* Evidence of invasive disease\n* Serious cardiovascular diseases",{"count":79,"type":21},50,"OBSERVATIONAL","This is a prospective, single-center, observational proof-of-principle clinical trial at the Department of Women's Health of the University Hospital Tübingen.",[27,83],"Cervical Cancer",{"date":61,"type":37},{"date":86,"type":37},"2023-12-27",{"date":88,"type":21},"2026-12",{"name":90,"class":44},"University Hospital Tuebingen",{"id":92,"slug":93,"hasResults":12,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":22,"phases":101,"briefSummary":102,"conditions":103,"keywords":113,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":122,"leadSponsor":124,"locationsCount":70},"100634904","phase-2-adjuvant-5-fluorouracil-following-thermal-ablation-to-improve-hpv-treatment-outcomes-in-women-with-hiv-in-kenya-100634904","NCT07545746","Adjuvant 5-Fluorouracil Following Thermal Ablation to Improve HPV Treatment Outcomes in Women With HIV in Kenya","Adjuvant 5-Fluorouracil Following Thermal Ablation to Improve HPV Treatment Outcomes in Women With HIV in Kenya : The ASCEND Trial","ASCEND","Inclusion Criteria\n\n* Women aged 25 years or older\n* Known HIV-positive status\n* On antiretroviral therapy (ART) for at least 60 days prior to enrollment\n* Positive HPV screening test screening result\n* Able to provide informed consent in English, Swahili, or Dholuo\n* Agree to use dual contraception during dosing phase if of childbearing potential\n* Planning to remain in study locale for duration of study (48 weeks) Exclusion Criteria\n* Current pregnancy or breastfeeding\n* History of anogenital cancer (cervical, vulvar, or anal)\n* Current use of immunosuppressive medications\n* History of total hysterectomy\n* Known allergy to 5FU\n* Medical comorbidity that would interfere with study participation\n* Unwilling or unable to use contraception during study participation",{"count":100,"type":21},140,[57],"This randomized, placebo-controlled trial will evaluate self-administered 5-fluorouracil (5FU) to improve human papillomavirus (HPV) clearance after thermal ablation (TA) in Women With Human Immunodeficiency Virus (HIV) (WWH) in Kenya. The trial will also assess the safety, adherence, and acceptability of 5FU. Starting four weeks after TA, participants will self-administer 5FU cream or matched placebo intravaginally once every other week for 12 applications, with clinic visits at weeks 2, 8, 16, 24, and 48 for evaluation. All participants will be followed up to 48 weeks.\n\nIt is hypothesized that, compared to placebo, 5FU will increase HPV clearance at 24 weeks and that the proposed dosing schedule will be safe, well-tolerated, and acceptable in this population. Together with data from other studies, this trial will provide evidence on the use of self-administered intravaginal 5FU to improve HPV treatment outcomes in WWH in low- and middle-income countries, where the burden of cervical cancer is highest.",[104,27,105,106,107,108,109,110,111,112],"HIV Infections","Cervix Cancer","CIN2","CIN3","CIN1","CIN","Cervical Intraepithelial Neoplasia Grade 3","Cervical Intraepithelial Neoplasia Grade 1","Cervical Intraepithelial Neoplasia Grade 2\u002F3",[114,115,116,117],"5-fluorouracil (5FU)","thermal ablation (TA)","placebo","intravaginal topical","2026-06-01",{"date":120,"type":37},"2026-06-02",{"date":39,"type":21},{"date":123,"type":21},"2028-03",{"name":125,"class":44},"UNC Lineberger Comprehensive Cancer Center",{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":138,"conditions":139,"keywords":140,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":149,"locationsCount":45},"100638010","clinic-vs-cliniccommunity-outreach-hpv-self-collection-to-increase-cervical-screening-in-women-living-with-hiv-100638010","NCT07624123","Clinic vs Clinic+Community Outreach HPV Self-Collection to Increase Cervical Screening in Women Living With HIV","Comparison of Clinic-based Versus Clinic-plus Community Outreach-based Strategy Via HPV Self-Collection to Increase Uptake of Cervical Cancer Screening Among Women Living With HIV: a Cluster Randomized Trial (CASCADE-3001-B)","C-3001B-P-CS7","Clinic Inclusion Criteria\n\n* Clinics selected for inclusion will include those clinics that provide Human Immunodeficiency Virus (HIV) care and distribute antiretroviral therapy (ART) to Women living with Human Immunodeficiency Virus (WLWH.\n* These clinics should also have the ability to collect their own data.\n* Such clinics could be supported by national programs and bilateral donor-funded initiatives\n\nInclusion Criteria for Medical Record Abstraction\n\n* Are living with Human Immunodeficiency Virus (HIV)\n* Are 25-49 years of age, or as recommended by the Zimbabwe National Screening Guidelines\n* Live in the catchment areas of or attend a study-eligible clinic\n* Are eligible for Human Papillomavirus (HPV)-based cervicovaginal testing either because:\n* They have never undergone cervical cancer screening before, or\n* They have never undergone HPV-based testing before and are now due for Visual Inspection with Acetic Acid and Cervicography (VIAC), per national guidelines, or\n* They have previously undergone HPV-based testing, and are now due for follow-up HPV-based testing per national guidelines, and \u002For\n* They underwent ablative or excisional treatment for presumed or confirmed cervical dysplasia \\>1 year ago and have not had any follow-up cervical cancer screening since treatment.\n\nExclusion Criteria for Medical Record Abstraction\n\n* Have had their cervix removed\n* Are pregnant or \\\u003C6 weeks post-delivery\n* Were positive on their most recent cervical cancer screening test and referred for further evaluation or treatment, but did not complete their referral\n* Have previously been treated for invasive cervical cancer","49 Years",{"count":136,"type":21},17734,[24],"This Clinical Trials Network for Human Immunodeficiency Virus (HIV)-Associated Cervical Cancer Screening and Treatment Optimization (CASCADE)-3001-B trial aims to assess how the introduction of a community-health-worker-facilitated model, in addition to the existing static clinic-only model, influences the rates of cervical cancer screening uptake among women living with HIV (WLWH). This study involves offering human papillomavirus (HPV) self-collection for cervical cancer screening to eligible WLWH.\n\nThe 'CASCADE' Network is a clinical trials network aimed at improving cervical cancer screening, management, and pre-cancer treatment for WLWH, in various healthcare settings. The network will conduct implementation trials to improve the triage of HPV-positive WLWH, as well as algorithms to optimize access to and options for effective treatment. Trials will be conducted using a mixed-methods approach aimed at assessing implementation strategies and outcomes and their potential to integrate into existing health systems.\n\nFurther understanding of HPV-based community-based strategies to reach WLWH, and the acceptability, feasibility, appropriateness, and cost of these strategies will be valuable for cervical cancer screening programs serving WLWH. Inputs from various 'CASCADE' Clinical Sites (CS) regarding feasible screening outreach options available in their settings for WLWH have guided this study that focuses on evaluating a pragmatic HPV self-collection implementation model to improve access to screening.\n\nWhile it is clear that HPV self-collection is a highly acceptable and feasible screening option, creating opportunities to conduct self-collection in alternative venues outside the clinic premises, and with the guidance of and facilitation by trusted community healthcare workers (CHWs) is an important implementation strategy that needs to be evaluated and considered for its potential benefit. Studies have not yet evaluated a community-based approach for HPV self-collection kit distribution among WLWH - who may have different characteristics, preferences, and access to screening services than women not living with HIV. Providing WLWH with the option of receiving HPV self-collection kits in their own homes or other community-based settings ('community-based HPV self-collection') is a novel implementation strategy that could improve cervical cancer screening rates among eligible women. Therefore, this novel trial aims to evaluate the feasibility and effectiveness of implementing community-based HPV self-collection among WLWH.",[105,104,27],[141,142],"self-collection","screening","2026-05-28",{"date":145,"type":37},"2026-06-03",{"date":147,"type":21},"2026-06",{"date":123,"type":21},{"name":125,"class":44},{"id":151,"slug":152,"hasResults":12,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":134,"enrollmentInfo":158,"targetDuration":4,"studyType":22,"phases":160,"briefSummary":161,"conditions":162,"keywords":163,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":169,"locationsCount":45},"100625876","clinic-vs-cliniccommunity-outreach-hpv-self-collection-to-increase-cervical-screening-in-women-with-hiv-100625876","NCT07428330","Clinic vs Clinic+Community Outreach HPV Self-Collection to Increase Cervical Screening in Women With HIV","Comparison of Clinic-based Versus Clinic-plus Community Outreach-based Strategy Via HPV Self-Collection to Increase Uptake of Cervical Cancer Screening Among Women Living With HIV: a Cluster Randomized Trial","CASCADE3001A","Clinic Inclusion Criteria\n\n* Clinics selected for inclusion will include those clinics that provide Human Immunodeficiency Virus (HIV) care and distribute antiretroviral therapy (ART) to Women living with Human Immunodeficiency Virus (WLWH.\n* These clinics should also have the ability to collect their own data.\n* Such clinics could be supported by national programs and bilateral donor-funded initiatives\n\nInclusion Criteria for Medical Record Abstraction\n\n* Are living with Human Immunodeficiency Virus (HIV)\n* Are 25-49 years of age, or as recommended by Uganda's Ministry of Health Cervical Cancer Prevention and Control Guidelines\n* Live in the catchment areas of or attend a study-eligible clinic\n* Are eligible for Human Papillomavirus (HPV)-based cervicovaginal testing either because:\n* They have never undergone cervical cancer screening before, or\n* They have never undergone HPV-based testing before and are now due for Acetic Acid (VIA), per national guidelines, or\n* They have previously undergone HPV-based testing, and are now due for follow-up HPV-based testing per national guidelines, and \u002For\n* They underwent ablative or excisional treatment for presumed or confirmed cervical dysplasia \\>1 year ago and have not had any follow-up cervical cancer screening since treatment.\n\nExclusion Criteria for Medical Record Abstraction\n\n* Have had their cervix removed\n* Are pregnant or \\\u003C3 months post-delivery\n* Were positive on their most recent cervical cancer screening test and referred for further evaluation or treatment, but did not complete their referral\n* Have previously been treated for invasive cervical cancer\n\nClinic Inclusion Criteria\n\n* Clinics selected for inclusion will include those clinics that provide Human Immunodeficiency Virus (HIV) care and distribute antiretroviral therapy (ART) to Women living with Human Immunodeficiency Virus (WLWH).\n* These clinics should also have the ability to collect their own data.\n* Such clinics could be supported by national programs and bilateral donor-funded initiatives",{"count":159,"type":21},7597,[24],"This Clinical Trials Network for Human Immunodeficiency Virus (HIV)-Associated Cervical Cancer Screening and Treatment Optimization (CASCADE) C3001-A trial aims to assess how the introduction of a community-health-worker-facilitated model, in addition to the existing static clinic-only model, influences the rates of cervical cancer screening uptake among women living with HIV (WLWH). This study involves offering human papillomavirus (HPV) self-collection for cervical cancer screening to eligible WLWH.\n\nThe 'CASCADE' Network is a clinical trials network aimed at improving cervical cancer screening, management, and pre-cancer treatment for WLWH, in various healthcare settings. The network will conduct implementation trials to improve the triage of HPV-positive WLWH, as well as algorithms to optimize access to and options for effective treatment. Trials will be conducted using a mixed-methods approach aimed at assessing implementation strategies and outcomes and their potential to integrate into existing health systems.\n\nFurther understanding of HPV-based community-based strategies to reach WLWH, and the acceptability, feasibility, appropriateness, and cost of these strategies will be valuable for cervical cancer screening programs serving WLWH. Inputs from various 'CASCADE' Clinical Sites (CS) regarding feasible screening outreach options available in their settings for WLWH have guided this study that focuses on evaluating a pragmatic HPV self-collection implementation model to improve access to screening.\n\nWhile it is clear that HPV self-collection is a highly acceptable and feasible screening option, creating opportunities to conduct self-collection in alternative venues outside the clinic premises, and with the guidance of and facilitation by trusted community healthcare workers is an important implementation strategy that needs to be evaluated and considered for its potential benefit. Studies have not yet evaluated a community-based approach for HPV self-collection kit distribution among WLWH - who may have different characteristics, preferences, and access to screening services than women not living with HIV. Providing WLWH with the option of receiving HPV self-collection kits in their own homes or other community-based settings ('community-based HPV self-collection') is a novel implementation strategy that could improve cervical cancer screening rates among eligible women. Therefore, this novel trial aims to evaluate the feasibility and effectiveness of implementing community-based HPV self-collection among WLWH.",[105,104,27],[142,141],"2026-05-26",{"date":143,"type":37},{"date":167,"type":37},"2026-02-03",{"date":123,"type":21},{"name":125,"class":44},{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":22,"phases":180,"briefSummary":181,"conditions":182,"keywords":188,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":45},"100636954","phase-2-phase-ii-study-of-dysplasix-intravaginal-suppositories-in-patients-patients-with-high-risk-hpv-and-mild-cervical-cytologic-abnormalities-100636954","NCT07572396","Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities","A Phase II, Randomized, Double-blind, Placebo-Controlled, Proof of Concept Study to Assess the Safety and Efficacy of Dysplasix™ Intravaginally-Administered Suppositories in Patients With High-Risk Human Papillomavirus (Hr-HPV) as Determined by HPV Testing, and Accompanied by Either (1) Atypical Squamous Cells of Undetermined Significance (ASC-US) or (2) Low-Grade Squamous Intraepithelial Lesions (LSIL), as Determined by Cytology","Inclusion Criteria:\n\nParticipants must meet all the following criteria to be eligible to enroll in the study:\n\n1. Participants capable of giving informed consent\n2. Females, ages 18 to 65 years old at the time of signature of the informed consent form.\n3. Participants who are able to correctly self-administer the intravaginal suppositories\n4. One or more hr-HPV oncotypes as confirmed by HPV test\n5. Participants with ASCUS or LSIL abnormalities as confirmed by cytology\n6. Immune competent\n7. Participants of childbearing potential must have a negative pregnancy test at screening.\n8. Participants of childbearing potential must agree to use appropriate contraception or abstain from sexual intercourse for the duration of the study\n9. Participants must not have received a recent HPV vaccination and must abstain from HPV vaccination until the end of study\n\nExclusion Criteria:\n\nParticipants meeting any of the following criteria will be excluded from the study:\n\n1. Presence of HSIL at screening cytology\n2. Evidence of glandular abnormalities (AGC\u002FAIS) at screening cytology\n3. BMI below 16\n4. Pregnant or nursing females\n5. Evidence of vaginal\u002Fvulval comorbidities, specifically, common sexually transmitted or vaginal infections, and bloodborne pathogens\n6. Using a vaginal contraceptive ring\n7. History of irregular menstrual cycles or routine intermenstrual bleeding\n8. Active autoimmune disease\n9. Taking prohibited concomitant medications\n10. Concurrent malignancy except for non-melanoma skin lesions\n11. Active participation in another clinical trial involving therapeutic intervention (unless ending within 30 days of screening date)","65 Years",{"count":179,"type":21},45,[57],"The goal of this clinical trial is to learn if an investigational vaginal suppository therapy works to treat low-grade cervical lesions (ASC-US and LSIL) associated with high-risk human papillomavirus (hr-HPV) infection in women. It will also learn about the safety and tolerability of this investigational therapy. The main questions it aims to answer are:\n\n* Does the investigational therapy lead to regression of cervical lesions?\n* Does the investigational therapy help clear hr-HPV infection?\n* Do any adverse effects occur from using this medical product?\n\nResearchers will compare the investigational therapy to a placebo (a look-alike substance that contains no active drug) to see if the investigational therapy works.\n\nParticipants will:\n\n* Be screened for hr-HPV, cervical abnormalities, and other conditions to be assessed for eligibility\n* Self-administer 15 doses of the investigational therapy or placebo as a vaginal suppository over 19 calendar days\n* Attend scheduled clinic visits for examinations, testing, and monitoring for a period of two months\n* Undergo assessments to evaluate cervical lesion status, hr-HPV infection, and safety outcomes\n* Keep a daily diary of investigational therapy use and associated information",[183,184,185,27,186,187],"High-risk HPV (Any Strain)","LSIL, Low Grade Squamous Intraepithelial Lesion","ASC-US","Cervical Abnormalities","Uterine Cervical Dysplasia",[189,190,108,191,192,193,194,195,196,197,198,199,200,201,202,203],"hpv","human papillomavirus","LSIL","EGCG","Quinine Sulfate","abnormal Pap","ASCUS","gynecology","precancerous lesions","atypical squamous cells","low grade squamous intraepithelial lesions","Epigallocatechin gallate","women's health","abnormal cytology","cervical cytology","2026-05-12",{"date":206,"type":37},"2026-05-14",{"date":208,"type":21},"2026-04-30",{"date":210,"type":21},"2027-01-27",{"name":212,"class":213},"Amplexd Therapeutics, Inc.","INDUSTRY",{"id":215,"slug":216,"hasResults":12,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":222,"sex":17,"minAge":223,"maxAge":177,"enrollmentInfo":224,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":226,"conditions":227,"keywords":229,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":239,"leadSponsor":241,"locationsCount":243},"100639641","priority-study-in-cervical-cancer-100639641","NCT07593066","PRIORITY Study in Cervical Cancer","The PRIORITY Study in Cervical Cancer: A Prospective Multicenter Observational Evaluation of an Integrated Molecular and Digital Model for Diagnostic Prioritization","PRIORITY","Inclusion Criteria:\n\n* Women aged 30 to 65 years\n* Eligible for cervical cancer screening according to national guidelines\n* Able and willing to provide informed consent\n* Able to perform self-sampling or attend clinical evaluation if required\n\nExclusion Criteria:\n\n* Previous diagnosis of cervical cancer\n* History of total hysterectomy (removal of the cervix)\n* Current pregnancy if it precludes study procedures according to clinical judgment\n* Any medical or social condition that, in the opinion of the investigators, would interfere with participation or follow-up",true,"30 Years",{"count":225,"type":21},700,"The PRIORITY study is a prospective, multicenter observational study designed to evaluate an integrated diagnostic model combining extended molecular self-sampling and digital colposcopy supported by telemedicine for the prioritization of women at risk of cervical cancer.\n\nThe study aims to assess the diagnostic performance, concordance, and clinical utility of this integrated approach in real-world settings, as well as its impact on diagnostic timeliness and patient navigation across different levels of care.\n\nParticipants will undergo standard-of-care evaluation, and data will be collected on molecular test results, colposcopic findings, diagnostic outcomes, and time intervals within the care pathway. No interventions are assigned as part of the study protocol.\n\nThe findings are expected to inform scalable strategies to improve early detection and optimize diagnostic pathways for cervical cancer, particularly in settings with structural and geographic barriers to timely care.",[83,228,27],"Cervical Intraepithelial Neoplasia",[230,231,232,233,234],"HPV self-sampling","Digital colposcopy","Telemedicine","Diagnostic prioritization","Cervical cancer screening","2026-05-11",{"date":237,"type":37},"2026-05-18",{"date":61,"type":21},{"date":240,"type":21},"2026-12-31",{"name":242,"class":44},"Pontificia Universidad Catolica de Chile",8,{"id":245,"slug":246,"hasResults":12,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":222,"sex":17,"minAge":18,"maxAge":177,"enrollmentInfo":251,"targetDuration":4,"studyType":22,"phases":253,"briefSummary":254,"conditions":255,"keywords":256,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":45},"100627809","feasibility-of-hpv-self-collection-kits-for-cervical-cancer-screening-100627809","NCT07453459","Feasibility of HPV Self-Collection Kits for Cervical Cancer Screening","Feasibility of Community-based Distribution of HPV Self-Collection Kits for At Home Cervical Cancer Screening","Inclusion Criteria:\n\n* Are age 25-65\n* Has an intact cervix\n* Self-reports that they have not been screened for cervical cancer within the last 3 years\n* Has a smartphone\n* Has access to the internet to engage with the Teal Health mobile app and complete a Zoom interview\n* Can read, speak, write and understand English well enough to take a survey and complete an interview\n\nExclusion Criteria:\n\n* Abnormal vaginal bleeding or discharge\n* A history of cancer of the reproductive system\n* A compromised immune system\n* Prior Diethylstilbestrol (DES) exposure\n* Currently pregnant or are within 6 weeks of giving birth\n* Treatment for a cervical precancer (e.g., loop electrosurgical excision procedure or conization) in the last 25 years.",{"count":252,"type":21},100,[24],"This study is testing and implementing an equity-focused, community-based intervention that improves women's access to cervical cancer screening and adherence to follow up after an abnormal result. The study's objective is to assess and compare the feasibility of different methods of distributing at-home HPV testing kits for cervical cancer screening among individuals who are under-screened.",[83,27],[234,257,258],"Self-collection","At-home HPV test","2026-04-19",{"date":261,"type":37},"2026-04-23",{"date":263,"type":37},"2026-04-17",{"date":265,"type":21},"2028-01-15",{"name":267,"class":44},"Washington University School of Medicine",{"id":269,"slug":270,"hasResults":12,"nctId":271,"briefTitle":272,"officialTitle":272,"acronym":273,"eligibilityCriteria":274,"healthyVolunteers":222,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":275,"targetDuration":4,"studyType":22,"phases":277,"briefSummary":278,"conditions":279,"keywords":280,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":45},"100610280","implementation-of-screen-treat-and-triage-for-women-living-with-hiv-in-la-romana-istar-100610280","NCT07225530","Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR)","(iSTAR)","Inclusion Criteria:\n\n* 25 years of age;\n* female sex assigned at birth (any gender identity);\n* HIV-positive;\n* women who have had cervical cancer precursor lesions which were removed more than 6 months ago; and\n* understand Spanish\n\nExclusion Criteria:\n\n* ages outside of the specified inclusion criteria;\n* women who are pregnant, less than 6 weeks postpartum, or in whom pregnancy cannot be excluded;\n* history of a Loop Electrosurgical Excision Procedure (LEEP) procedure in the last 6 months;\n* history of a hysterectomy;\n* previous diagnosis of gynecological cancer;\n* history of cancer of the anogenital tract; or\n* unable or unwilling to provide informed consent",{"count":276,"type":21},600,[24],"This study aims to conduct a randomized controlled trial to evaluate the effectiveness of same-day HPV-based screen and treat among women living with HIV (WLH) in La Romana, Dominican Republic. With cervical cancer being a leading cause of cancer-related deaths in women living with HIV, and cervical cancer deaths being preventable through screening and early detection, this project seeks to identify factors associated with the successful implementation of the Screen, Triage, and Treat approach to inform future implementation and scale-up.",[104,27,83],[281,234,282,27],"People living with HIV (PLWH)","Spanish speakers","2026-02-24",{"date":285,"type":37},"2026-02-25",{"date":287,"type":37},"2026-02-23",{"date":289,"type":21},"2029-11-01",{"name":291,"class":44},"Columbia University",{"id":293,"slug":294,"hasResults":12,"nctId":295,"briefTitle":296,"officialTitle":296,"acronym":297,"eligibilityCriteria":298,"healthyVolunteers":222,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":299,"targetDuration":4,"studyType":22,"phases":301,"briefSummary":302,"conditions":303,"keywords":314,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":336},"100614592","evaluation-of-the-q-pad-hrhpv-test-system-for-identifying-precancer-100614592","NCT07281599","Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer","EQUIP","Inclusion Criteria:\n\n* You are 25 years old or older and have an intact cervix.\n* You were referred for a colposcopy after an abnormal Pap or HPV screen.\n* Your periods come regularly-about every 21-35 days.\n* You own a smartphone, have an email address, and can read the Qvin app instructions in English.\n* You are willing to sign the consent form (electronically).\n* You agree to use a condom for any vaginal intercourse or shared penetrative toy use from Q-Pad collection until the colposcopy visit if engaging with a new sexual partner during this period.\n\nExclusion Criteria:\n\n* You are pregnant or think you might be.\n* You are unwilling or unable to use the two Q-Pads and mail them back (mailing costs are covered).\n* You had treatment for cervical pre-cancer (CIN2+)-such as LEEP, cone, or ablation-within the last 12 months.\n* You have already joined this study or are in another cervical-screening \u002F HPV study right now.",{"count":300,"type":21},450,[24],"The EQUIP Study is testing whether high-risk human papillomavirus (hrHPV), the virus that causes most cervical cancers, can be accurately detected from menstrual blood collected at home. People who have been referred for colposcopy after an abnormal Pap or hrHPV test will use the Q-Pad Kit during their period to collect menstrual samples on a special menstrual pad and mail them to a central laboratory for hrHPV testing.\n\nThe same participants will have a standard cervical sample collected for routine hrHPV testing and will undergo colposcopy as part of their usual care. By comparing hrHPV results from menstrual samples with results from cervical samples and biopsy findings, the study will evaluate how well the Q-Pad hrHPV Test System detects cervical precancer and will also assess how easy and acceptable it is for participants to use this at-home collection method.",[27,304,305,306,307,308,309,310,311,312,313],"HPV 16 Infection","High Risk HPV","Cervical Cancer Screening","Cervical Cancer Cin Grade","Cervical Cancer (Early Detection)","HPV","HPV (Human Papillomavirus)-Associated","HPV DNA","HPV Infections","Screening Test",[315,316,257,317,318,319,320,321,322,323,309,324,325,326],"Q-Pad","Self-sampling","self-collect","cervical cancer screening","menstural blood","Sexually Transmitted Diseases, Viral","Sexually Transmitted Diseases","Genital Diseases","Papillomavirus Infections","high risk HPV","pap smear","at-home collection","2026-01-29",{"date":329,"type":37},"2026-02-02",{"date":331,"type":37},"2025-12-01",{"date":333,"type":21},"2027-03",{"name":335,"class":213},"Qurasense",4,{"id":338,"slug":339,"hasResults":12,"nctId":340,"briefTitle":341,"officialTitle":342,"acronym":4,"eligibilityCriteria":343,"healthyVolunteers":222,"sex":17,"minAge":53,"maxAge":344,"enrollmentInfo":345,"targetDuration":4,"studyType":22,"phases":347,"briefSummary":349,"conditions":350,"keywords":353,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":361,"locationsCount":243},"100459391","phase-3-a-phase-iii-clinical-trial-of-a-11-valent-recombinant-human-papillomavirus-vaccine-hansenulapolymorpha-in-chinese-women-aged-9-45-years-100459391","NCT05262010","A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years","A Multicenter Randomized, Blinded, Placebo-controlled Phase III Clinical Trial Evaluating the Protective Efficacy, Safety and Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years","Inclusion Criteria:\n\n\\- non-gynecological related\n\n1. \\*Chinese women with a history of sexual life who are 18-45 years old at the time of enrollment and can provide legal identification;\n2. \\*Axillary body temperature \\\u003C37.3℃ on the day of enrollment;\n3. The subjects themselves have the ability to understand the clinical trial and voluntarily sign the informed consent;\n4. Subjects have the ability to read, understand, and fill out research application forms such as diary cards\u002Fcontact cards, and promise to follow the research requirements participate in follow-up visits;\n5. No previous HPV vaccination history, no commercially available HPV vaccine during the study period (about 6 years after enrollment) plan of;\n6. The subject has a negative urine pregnancy test on the day before vaccination.\n\n   \\- Gynecology related\n7. \\*Effective contraception was taken from day 1 of last menstrual cycle to day 0 of the study, and no childbearing within 7 months after enrollment plan.\n8. \\*Before the gynecological visit and within 48 hours before any subsequent visit that includes a gynecological sample collection: asexual life (including same-sex or opposite-sex anal, vaginal or genital contact), unwashed\u002Fwashed vagina (Except for normal bathing outside the vagina）, no vaginal drugs or preparations are used.\n\nExclusion Criteria:\n\nFirst dose exclusion criteria:\n\n(Visits may be rescheduled if the criteria described in the \"\\*\" option are met at screening)\n\n\\- Non-gynecological related\n\n1. \\* Those with abnormal blood pressure (systolic blood pressure ≥ 140mmHg and\u002For diastolic blood pressure ≥ 90mmHg) on physical examination before vaccination;\n2. \\*3 months prior to vaccination or planned to receive any immune globulin or blood products within 7 months of enrollment;\n3. \\*Received any vaccine within 14 days prior to vaccination, or received live vaccine within 28 days;\n4. \\*3 days before vaccination, suffering from acute febrile illness (body temperature ≥38.5℃) or using antipyretic, analgesic and antiallergic drugs (eg: acetaminophen, ibuprofen, aspirin, loratadine, cetirizine, etc.);\n5. History of severe allergies\u002Fconditions requiring medical intervention (e.g. Anaphylactic shock, anaphylactic laryngeal edema, anaphylactoid purpura, thrombocytopenic purpura, local allergic necrosis(Arthus reaction) etc.);\n6. Immunocompromised or diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia Blood disease, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammation STD or other autoimmune disease;\n7. 1 month before vaccination or plan to receive immunosuppressive therapy within 7 months after enrollment, such as oral administration for more than 2 consecutive weeks Oral or injectable systemic corticosteroid therapy (≥2 mg\u002Fkg\u002Fday or ≥20 mg\u002Fday prednisone or equivalent to prednisone) amount); however, topical medications (such as ointments, eye drops, inhalers, or nasal sprays) are not limited;\n8. Previous splenectomy or impaired spleen function;\n9. Those with previous or current severe liver, kidney and cardiovascular diseases, complicated diabetes, and malignant tumors;\n10. Have a history of epilepsy, convulsions, mental illness or a family history of mental illness;\n11. Suffering from thrombocytopenia or any coagulation disorder that can become a contraindication to intramuscular injection;\n12. Participate in other clinical studies (drugs, vaccines and medical devices) within 3 months before vaccination or during the planned study period;\n13. The investigator believes that the subject has any other factors that are not suitable for participating in the clinical trial (such as: poor compliance or planning Permanent relocation from the area before the study is completed, etc.).\n\n    \\- Gynecology related\n14. \\*Pregnant, breastfeeding, or within 6 weeks of pregnancy at the time of the first dose of the vaccine;\n15. \\*The subject is in the menstrual period;\n16. \\*Acute lower genital tract infection (such as acute vulvitis\u002Fvaginitis\u002Fcervicitis, etc.) found by the naked eye during gynecological examination;\n17. Previous history of abnormal cervical cancer screening or lesions (including HPV DNA positive, squamous intraepithelial lesion (SIL)or atypical squamous cells of undetermined significance (ASC-US), atypical squamous epithelial cells - excluding high-grade squamous cells Intraepithelial lesions (ASC-H), atypical glandular cells (AGC) or with cervical intraepithelial neoplasia (CIN),Adenocarcinoma in situ (AIS) or cervical cancer, etc.);\n18. Past or current anal and genital diseases (such as vulvar intraepithelial neoplasia, vaginal intraepithelial neoplasia, genital warts,vulvar cancer, vaginal cancer and anal cancer, etc.);\n19. Previous hysterectomy or pelvic radiation therapy or severe cervical\u002Fvaginal dysplasia.\n\nExclusion criteria for 2nd and 3rd dose vaccination：\n\nIf any of the following occurs, the investigator will terminate the subject's vaccination with the investigational vaccine.\n\n* Meet the first dose exclusion criteria 5, 6, 7, 8, 9, 12;\n* Any other reasons that, in the judgment of the investigator, warrant discontinuation of the investigational vaccination.","45 Years",{"count":346,"type":21},13500,[348],"PHASE3","A total of 13500 Chinese women aged 18-45 years old were divided into three age groups: 18-26 years old, 27-35 years old, and 35-45 years old. The experimental group and the placebo group were randomly assigned in a ratio of 1:1. All subjects enrolled in the upper arm deltoid muscle were injected with 3 doses of test vaccine or placebo according to the 0, 2, and 6 months immunization program.",[351,352],"HPV InfectioN","HPV-Related Carcinoma",[354],"HPV Infection HPV vaccine","2026-01-15",{"date":357,"type":37},"2026-01-16",{"date":359,"type":37},"2022-06-04",{"date":41,"type":21},{"name":362,"class":213},"National Vaccine and Serum Institute, China",{"id":364,"slug":365,"hasResults":12,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":4,"eligibilityCriteria":369,"healthyVolunteers":222,"sex":17,"minAge":18,"maxAge":177,"enrollmentInfo":370,"targetDuration":4,"studyType":22,"phases":372,"briefSummary":373,"conditions":374,"keywords":377,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":390,"locationsCount":45},"100618785","popsci-chw4cervixhealth-100618785","NCT07336134","PopSci CHW4CervixHealth","Uptake of HPV Self-sampling in Underserved Minority Women Using a Community Health Worker Model: Comparison of Evalyn Brush and Copan Floqswab","Inclusion Criteria:\n\nPhase I:\n\n* Women aged 25-65 years\n* Scheduled for a Pap smear test appointment at Jefferson OBGYN Center City location\n* Willing and able to provide informed consent for participation in the study\n* Agree to perform an HPV self-collection collection procedure during the same visit\n* Have not undergone a hysterectomy (intact cervix required)\n\nPhase II:\n\nThis intervention targets under-screened minority individuals who must meet all the following inclusion criteria to be eligible to participate in the study:\n\n* Women aged 25-65 years\n* Who has not had a Pap smear in the past three to five years based on age of prior screening and type of screening. If under the age of 30, in the past 3 years and if over the age of 30, in the past 5 years. Participant will self-report normal pap smear and date.\n* Self-identify as Hispanic, Black\u002FAfrican or Black Caribbean, Chinese, Korean, or Vietnamese\n* Competent to give consent and provide signed and dated informed consent form in their preferred language.\n\nExclusion Criteria:\n\nPhase I:\n\n* Current pregnancy (self-reported or confirmed)\n* Previous participation in an HPV self-collection study within the past 12 months\n* Presence of visible vaginal or cervical infection or symptoms suggestive of a current genital tract infection\n* Inability to comply with study procedures or follow instructions (e.g., due to language barriers or cognitive impairments)\n\nPhase II:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Have a history of hysterectomy, cervical cancer\n* Self-report participation in a cervical cancer screening or other prevention study\n* Pregnant (self-reported)\n* Inability to provide informed consent",{"count":371,"type":21},120,[24],"Phase I: Validating self-collection kit by comparing their results with clinical Pap smear results in a cohort of 20 patients.\n\nPhase II: Evaluate the feasibility and acceptability of the CHW4CervicalHealth: Use of a self-collection kit to improve cervical health screening intervention aimed to promote HPV self-collection uptake among screening-eligible and under-screened ethnic minority women in the community.",[83,375,376,27],"Hpv","Human Papilloma Virus",[378,379,380,141,381,382,383],"Copan FLOQswab","Evalyn® Brush","HPV self-collection","community health workers","underscreened women","concordance","2026-01-09",{"date":386,"type":37},"2026-01-13",{"date":388,"type":37},"2025-10-22",{"date":63,"type":21},{"name":391,"class":44},"Thomas Jefferson University",{"id":393,"slug":394,"hasResults":12,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":4,"eligibilityCriteria":398,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":399,"targetDuration":4,"studyType":22,"phases":401,"briefSummary":402,"conditions":403,"keywords":404,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":45},"100551282","pocket-colposcopy-using-care-algorithm-100551282","NCT06458062","Pocket Colposcopy Using CARE Algorithm","Development and Validation of an Artificial-Intelligence-enabled Portable Colposcopy Device for Optimizing Triage Alternatives for HPV-based Cervical Cancer Screening","Inclusion Criteria:\n\n1. Age ≥ 30 years old and ≤ 64 years old; or Age ≥ 25 years old if women living with HIV (WLWH)\n2. Sex: Female\n3. Positive HPV test within past 6 months\n\nExclusion Criteria:\n\n1. Pregnant women (cannot perform a cervical biopsy on a patient who is pregnant unless absolutely indicated)\n2. Women with a negative HPV test within the past 9 months\n3. Patients incapable of giving informed consent\n4. Women with a history of cervical cancer\n5. Pelvic exam concerning for cervical cancer or cervical infection\n6. History of hysterectomy",{"count":400,"type":21},1079,[24],"The Pocket colposcope has 510k FDA clearance and has been successfully used in \\~2500 unique patients globally in Duke and non-Duke protocols to date. 1054 women who are HPV(+) and planned to undergo treatment at four Ministry of Health-supported outpatient clinics in Kisumu County will be recruited to the study. After providing informed consent, participants will be proceed with colposcopy using the POCKET colposcope.",[83,27],[405,406,318],"HPV testing","colposcopy","2026-01-08",{"date":409,"type":37},"2026-01-12",{"date":411,"type":37},"2024-02-15",{"date":413,"type":21},"2027-04-30",{"name":415,"class":44},"Duke University",{"id":417,"slug":418,"hasResults":12,"nctId":419,"briefTitle":420,"officialTitle":420,"acronym":421,"eligibilityCriteria":422,"healthyVolunteers":12,"sex":423,"minAge":18,"maxAge":177,"enrollmentInfo":424,"targetDuration":4,"studyType":22,"phases":426,"briefSummary":427,"conditions":428,"keywords":430,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":437,"locationsCount":4},"100619416","evaluation-of-the-effect-of-a-dietary-supplement-based-on-egcg-vitamin-b12-hyaluronic-acid-and-folic-acid-on-the-maintenance-of-physiological-balance-and-the-natural-defenses-of-the-male-genital-system-in-subjects-exposed-to-hpv-infection-100619416","NCT07344337","Evaluation of the Effect of a Dietary Supplement Based on EGCG, Vitamin B12, Hyaluronic Acid, and Folic Acid on the Maintenance of Physiological Balance and the Natural Defenses of the Male Genital System in Subjects Exposed to HPV Infection.","PERVI-I","Inclusion Criteria:\n\n* Signed informed consent\n* Couple seeking pregnancy\n* Male partner aged 25-65 years\n* HPV DNA test indicating active HPV infection in the male partner\n* HPV DNA test indicating negativity for HPV infection in the female partner\n\nExclusion Criteria:\n\n* Concomitant diseases causing immunosuppression\n* Treatment with immunomodulatory therapies\n* Use of EGCG or other green tea extracts","ALL",{"count":425,"type":21},96,[24],"This is a randomized pilot interventional study aimed at evaluating the effect of a dietary supplement containing EGCG, vitamin B12, hyaluronic acid, and folic acid on the maintenance of physiological balance and natural defenses of the male genital tract in subjects exposed to HPV infection and seeking care for infertility at natural procreation centers. The study includes 48 couples (96 participants) recruited at the International Scientific Institute \"Paolo VI\" of the A. Gemelli Policlinico, randomly assigned to two groups: 24 couples in which both partners receive one oral tablet per day of the supplement for 6 months, and 24 control couples receiving no supplementation. In addition to the primary objective, secondary outcomes assess potential support of sperm parameters, reproductive well-being of the couples, maintenance of genital mucosal physiological balance with possible reduction of HPV transmission risk to female partners, and support of physiological balance in the presence of co-infections or alterations of the genital microbiota.",[27,429],"Infertilities",[309,431],"INFERTILITY","2026-01-07",{"date":355,"type":37},{"date":435,"type":21},"2026-03",{"date":123,"type":21},{"name":438,"class":44},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":440,"slug":441,"hasResults":12,"nctId":442,"briefTitle":443,"officialTitle":444,"acronym":4,"eligibilityCriteria":445,"healthyVolunteers":222,"sex":423,"minAge":446,"maxAge":344,"enrollmentInfo":447,"targetDuration":4,"studyType":22,"phases":449,"briefSummary":450,"conditions":451,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":460,"locationsCount":45},"100574206","phase-2-to-evaluate-the-safety-and-immunogenicity-of-15-valent-hpv-recombinant-vaccine-in-chinese-people-aged-9-45-years-100574206","NCT06756269","To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years","A Randomised, Double-blind, Placebo and Positive Controlled, Phase 2 Clinical Trial to Evaluate the Safety and Immunogenicity of 15-valent Human Papillomavirus Recombinant Vaccine (Hansenulapolymorpha) in Healthy Chinese People Aged 9-45 Years","Inclusion Criteria:\n\n1. Participants aged 9-45；\n2. Participants aged 18-45 who can provide legal identification，participants aged 9-17 and their guardian can provide legal identification；\n3. Participants and\u002For their guardian sign an informed consent form;\n4. Axillary temperature less than 37.3 ℃（\\>14 years old）or less than 37.5℃（≤14 years old）at the time of enrollment；\n5. Be able to comply with study protocol requirements；\n6. Women with reproductive age take effective contraceptive measures within 2 weeks before enrollment in the study, and were not pregnant at the time of enrollment (negative blood pregnancy test), did not have lactation period, and had no birth plan within the 30 days after receiving the whole vaccination;\n7. Agree to take effective contraceptive measures within 30 days after receiving the whole vaccination (effective contraceptives include: oral contraceptives, injection or embedding contraceptives, sustained release topical contraceptives, hormone patches, intrauterine devices), sterilization, abstinence, condoms (male), diaphragms, cervical caps, etc.\n\nExclusion Criteria:\n\n1. Have been vaccinated with other HPV vaccines or planned to vaccinate other HPV vaccines during the study period；\n2. Plan to participate other clinical trials during the study period，or participated other clinical trials （including vaccine or drug）and received medication or vaccine within 3 months before enrollment ,\n3. History of positive HPV testing (including types not covered by the trial vaccine) among the participants aged 18-45 years old;\n4. History of CIN2\u002FAIS\u002FCervical Cancer\u002FPelvic radiation therapy in female participants;\n5. History of HPV-related external genital diseases (such as genital warts, Vulvar intraepithelial neoplasia, Vaginal intraepithelial neoplasia, Penis\u002Fperianal\u002Fperineum intraepithelial neoplasia, Penile\u002Fperianal\u002Fperineal cancer) 、anal intraepithelial neoplasia and related cancer, or head and neck cancer；history of sexually transmitted diseases (including syphilis， Gonorrhea, genital chlamydia infection, genital herpes, soft chancre, sexually transmitted lymphogranuloma, inguinal granuloma, etc.);\n6. Has been diagnosed as having congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection\u002FAIDS, SCID; Or Autoimmune Diseases (such as systemic lupus erythematosu, Rheumatoid arthritis, juvenile Rheumatoid arthritis, Pernicious Anemia, Ulcerative colitis, Type 1 diabetes, Graves' disease, hashimoto thyroiditi, etc.);\n7. History of convulsions, epilepsy, except of febrile convulsions in children 5 years of age and younger;\n8. History of severe allergy that requires medical intervention, including but not limited to severe adverse reactions caused by vaccine or drug, eg anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenia sexual purpura, local allergic necrosis (Arthus reaction), widespread urticaria, dyspnea, angioedema, etc.; History of severe side effect caused by vaccination or severe allergy to any of the components of the investigational vaccine, including histidine, sodium chloride, aluminium phosphate, Polysorbate 80 and water for injection;\n9. Severe diseases, as determined by the investigator, that affect vaccination eligibility, whether past or current, include severe cardiovascular disease, severe liver and kidney disease, malignant tumor, and serious infectious disease, such as: tuberculosis, viral hepatitis, etc.;\n10. Before the enrollment, the physical examination was untreatment or uncontrolled hypertension, (18-45 year old: systolic blood pressure ≥140mmHg and \u002F or diastolic blood pressure ≥90mmHg, 9-17 year old: systolic blood pressure ≥120mmHg and \u002F or diastolic blood pressure ≥80mmHg);\n11. Coagulation disorders: such as Congenital or acquired hemophilia, Coagulation factor deficiency, clotting disorders, thrombocytopenia, etc.;\n12. No spleen or functional spleen, and no spleen caused by any condition;\n13. Receive any Immunosuppressive therapy product within 1 month prior to the first vaccination, or plan to receive such product from Day 0 to Month 7 (30 days after receiving the third dose of vaccination)，e.g. systemic medication for glucocorticoid (\\>20mg\u002Fday or 2mg\u002Fkg\u002Fday, continuous use ≥2 weeks), but local medication can be used (such as ointment, eye drops, inhalants) Or nasal spray);\n14. Receive any immunoglobulin or blood product within 3 months prior to the first injection, or plan to receive such product from Day 0 to Month 7 (30 days after receiving the third dose of vaccination);\n15. 3 days before vaccination, suffering from acute illness or acute exacerbation of chronic disease; using fever reducer, Antihistamines, and Analgesics(such as: Acetaminophen, Ibuprofen, loratadine, Cetirizine, etc. )\n16. Receiving inactivated vaccine or recombinant vaccine or live-attenuated vaccine or nucleic acid vaccine or adenovirus vaccine within 14 days before vaccination;\n17. History of mental disorders or family history of mental health disorder (immediate family);\n18. Plan to move out of the city before the end of the study or leave the local area for a long time during the scheduled study visit;\n19. The investigator believes that the participant has any condition that may interfere with the assessment of the purpose of the study.","9 Years",{"count":448,"type":21},330,[57],"To evaluate the safety and Immunogenicity of 15-valent HPV vaccine in 9-45year-old participants.",[27,352,452,453],"HPV-Related Intraepithelial Neoplasia","Genital Wart","2025-12-16",{"date":456,"type":37},"2025-12-17",{"date":458,"type":37},"2025-01-15",{"date":386,"type":21},{"name":461,"class":213},"Shanghai Bovax Biotechnology Co., Ltd.",{"id":463,"slug":464,"hasResults":12,"nctId":465,"briefTitle":466,"officialTitle":466,"acronym":467,"eligibilityCriteria":468,"healthyVolunteers":12,"sex":423,"minAge":223,"maxAge":4,"enrollmentInfo":469,"targetDuration":4,"studyType":22,"phases":471,"briefSummary":472,"conditions":473,"keywords":474,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":484,"locationsCount":70},"100555117","concordance-and-acceptability-of-self-screening-versus-screening-by-a-healthcare-professional-for-hpv-a-risk-factor-for-anal-cancer-by-swab-in-people-living-with-hiv-100555117","NCT06507917","Concordance and Acceptability of Self-screening Versus Screening by a Healthcare Professional for HPV, a Risk Factor for Anal Cancer, by Swab in People Living With HIV","a-HPVVIH","Inclusion Criteria:\n\nPatient :\n\n* living with HIV\n* aged 30 or over\n* resident on Reunion island and followed at the University Hospital of Reunion Island (the only follow-up center on the island)\n* Able to perform anal self-sampling\n* Able to answer a questionnaire\n* Affiliated with or benefiting from a social security scheme\n* Have given free, informed and signed consent\n\nExclusion Criteria:\n\n* People with a previous anal swab less than 7 days old\n* Persons with a known current diagnosis of anal cancer\n* Persons deprived of liberty by judicial or administrative decision, minors, and persons under legal protection: guardianship or curators",{"count":470,"type":21},398,[24],"Anal canal cancers are on the increase in France, with around 2,000 new cases per year. These lesions can be detected by directed biopsies or smear tests.\n\nThe incidence rate of anal cancer is 30 times higher in people living with HIV than in the general population.\n\nAccording to a recent study, the risk of anal cancer is highest in this population, but is also high in heterosexual men over 30 and women over 30. However, the proposal of a proctological examination in this population is not systematic.\n\nIn France, there is no HPV screening for people living with HIV, but there is a recommendation for proctology consultation in certain cases, notably for men who have sex with men (MSM) or for women with vaginal cervical lesions.\n\nSeveral oncogenic HPV serotypes have been identified in the genesis of anal cancer. The serotype identified as the most carcinogenic is HPV-16 (89%).\n\nThis study will look at anal HPV screening in people over 30 living with HIV, thus including a population for which no screening is currently offered (heterosexual men living with HIV and women living with HIV without vaginal cervical lesions), and will assess the concordance and acceptability of self-screening versus screening by a healthcare professional as part of a comprehensive anal cancer screening strategy in this population.",[27],[309,475,476],"HIV","anal screening","2025-12-04",{"date":479,"type":37},"2025-12-11",{"date":481,"type":37},"2025-11-28",{"date":483,"type":21},"2027-01-02",{"name":485,"class":44},"Centre Hospitalier Universitaire de la Réunion",{"id":487,"slug":488,"hasResults":12,"nctId":489,"briefTitle":490,"officialTitle":490,"acronym":491,"eligibilityCriteria":492,"healthyVolunteers":222,"sex":423,"minAge":53,"maxAge":4,"enrollmentInfo":493,"targetDuration":4,"studyType":22,"phases":494,"briefSummary":495,"conditions":496,"keywords":498,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":500,"lastUpdatePostDateStruct":501,"startDateStruct":502,"completionDateStruct":504,"leadSponsor":506,"locationsCount":509},"100556219","identification-of-molecular-signatures-of-high-risk-oncogenic-hpv-and-study-of-their-associations-with-the-presence-of-high-grade-lesions-andor-anal-cancer-10-years-after-inclusion-in-the-anrs-ipergay-trial-100556219","NCT06522256","Identification of Molecular Signatures of High-risk Oncogenic HPV and Study of Their Associations With the Presence of High-grade Lesions and\u002For Anal Cancer 10 Years After Inclusion in the ANRS IPERGAY Trial","HPVsign","Inclusion Criteria:\n\n* Participant in the ANRS IPERGAY clinical trial who was included in the initial HPV sub-study;\n* Informed and written signed consent\n* Participant with regular health insurance\n\nExclusion Criteria:\n\n* Participant under guardianship or curatorship\n* Participant with free State medical assistance\n* Participant who disagrees with the use of data collected as part of their participation in the ANRS IPERGAY trial.",{"count":252,"type":21},[24],"HPVsign is a cross-sectional, non-comparative, multicenter study involving all participants included in the HPV substudy of the ANRS IPERGAY trial. The study proposes to evaluate the cumulative incidence of high-grade lesions and\u002For anal cancers using high-resolution anoscopy (HRA) during the HPVsign study and\u002For diagnosed since the end of participation in the ANRS IPERGAY trial.",[27,497],"Anal Cancer",[499],"HSIL","2025-11-27",{"date":477,"type":37},{"date":503,"type":37},"2025-03-20",{"date":505,"type":21},"2027-07-30",{"name":507,"class":508},"ANRS, Emerging Infectious Diseases","OTHER_GOV",3,{"id":511,"slug":512,"hasResults":12,"nctId":513,"briefTitle":514,"officialTitle":515,"acronym":4,"eligibilityCriteria":516,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":177,"enrollmentInfo":517,"targetDuration":4,"studyType":22,"phases":518,"briefSummary":519,"conditions":520,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":522,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":528,"locationsCount":45},"100538017","the-effect-of-the-association-egcg-folic-acid-and-vitamin-b12-in-preventing-the-persistence-of-hpv-infection-100538017","NCT06285357","The Effect of the Association EGCG, Folic Acid and Vitamin B12 in Preventing the Persistence of HPV Infection.","A Pilot Study to Test the Effect of the Association of Epigallocatechin Gallate (EGCG), Folic Acid and Vitamin B12 in Preventing the Persistence of Human Papilloma Virus (HPV) Infection.","Inclusion Criteria:\n\n* HR-HPV DNA test positivity\n\nExclusion Criteria:\n\n* No HSIL",{"count":252,"type":21},[24],"The purpose of the study is to test the effect of the administration of a dietary supplement consisting of epigallocatechin gallate (EGCG), vitamin B12 and folic acid in the treatment of infections with papilloma virus of the cervix.",[27],"2025-11-19",{"date":523,"type":37},"2025-11-20",{"date":525,"type":37},"2024-02-19",{"date":527,"type":21},"2026-08",{"name":529,"class":213},"Lo.Li.Pharma s.r.l",{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":535,"acronym":4,"eligibilityCriteria":536,"healthyVolunteers":222,"sex":17,"minAge":537,"maxAge":344,"enrollmentInfo":538,"targetDuration":4,"studyType":22,"phases":540,"briefSummary":542,"conditions":543,"keywords":546,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":551,"startDateStruct":553,"completionDateStruct":555,"leadSponsor":557,"locationsCount":45},"100490961","phase-4-comparing-immune-response-of-2-vs-3-hpv-doses-27-45-years-old-100490961","NCT05672927","Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)","Comparison of the Immune Response After Administration of 2 vs. 3 Doses of the FDA-approved 9-Valent HPV Vaccine Among Women 27-45 Years of Age","Inclusion criteria:\n\n1. Females 27-45 years old.\n2. Ability to give informed consent.\n3. Has not received any prior doses of the HPV vaccine. This will be verified by the person and state registry (Immtrac), as well as the person's electronic medical record.\n4. Reliable telephone access for the duration of the project.\n5. Can read and speak in either English or Spanish.\n6. Identified source of funding for vaccine such as Medicaid, private health insurance, Texas Healthy Women program, etc.\n7. Reports consistent use of reliable birth control and plans to continue its use through study month 13.\n\nExclusion criteria:\n\n1. Currently pregnant or plans to become pregnant or donate eggs in the next 13 months. Any subjects with positive pregnancy tests at the initial visit will be disqualified from the study and advised to seek prenatal care.\n2. Has an immunodeficiency or autoimmune disease such as HIV infection, lymphoma, leukemia, lupus, rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition.\n3. Currently receiving treatment or medication that can suppress immune function including radiation therapy, chemotherapy, cyclosporin, leflunomide (Arava), TNF-α antagonists, monoclonal antibody therapies (including rituximab \\[Rituxan\\]), intravenous gamma globulin (IVIG), antilymphocyte sera, other therapy known to interfere with the immune response, or systemic corticosteroids (by mouth or intramuscular injection). Those using or have used steroids that are inhaled, placed in the eye, applied on the skin, or injected into the joint\u002Fsoft tissue will be considered eligible for the study.\n4. History of splenectomy\n5. Known allergies to any vaccine components, including aluminum, yeast or Benzonase.\n6. Febrile at ≥100°F in the 24 hours prior to vaccination. The patients may be rescheduled for a later date.\n7. History of thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.\n8. History of \\>10 sexual partners in their lifetime at time of enrollment\n9. Plans to move out of the Galveston\u002FHouston area in the 13 months following study entry.","27 Years",{"count":539,"type":21},618,[541],"PHASE4","The goal of this clinical trial is to compare a 2-dose and 3-dose series of 9vHPV vaccine among 27-45-year-old females to assess if 2 doses elicit a noninferior immune response. Participants will be randomized 1:1 to either the 2-dose group or the 3-dose group and asked to provide 4 blood samples over a period of 12 months. All 2-dose participants will be offered a 3rd dose after the final blood draw,12 months after their initial vaccination.",[544,27,545],"Immunization","Human Papillomavirus",[547,548,549],"HPV vaccination","Gardasil 9","Noninferiority trial","2025-10-02",{"date":552,"type":37},"2025-10-06",{"date":554,"type":37},"2023-01-18",{"date":556,"type":21},"2027-08",{"name":558,"class":44},"The University of Texas Medical Branch, Galveston",{"id":560,"slug":561,"hasResults":12,"nctId":562,"briefTitle":563,"officialTitle":564,"acronym":565,"eligibilityCriteria":566,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":567,"enrollmentInfo":568,"targetDuration":4,"studyType":22,"phases":570,"briefSummary":571,"conditions":572,"keywords":577,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":589,"startDateStruct":590,"completionDateStruct":592,"leadSponsor":593,"locationsCount":595},"100370084","phase-2-artesunate-vaginal-inserts-for-the-treatment-of-cervical-intraepithelial-neoplasia-cin23-100370084","NCT04098744","Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2\u002F3)","A Phase II Double Blind, Placebo-controlled, Randomized Trial of Artesunate Vaginal Inserts for the Treatment of Patients With Cervical Intraepithelial Neoplasia (CIN2\u002F3)","ART-CIN_IIB","Inclusion Criteria:\n\n* Adult females age ≥ 25 years\n* Capable of informed consent\n* Any HPV genotype detectable by DNA test\u002FHPV genotyping\n* Colposcopically-directed, histologically confirmed tissue diagnosis of cervical high grade squamous intraepithelial lesions (CIN2, CIN3, or CIN2\u002F3)\n* Women of childbearing potential agree to use birth control through week17 of the study.\n* Weight ≥ 50kg\n\nExclusion Criteria:\n\n* Pregnant and nursing women\n* Active autoimmune disease\n* Taking immunosuppressive medication\n* HIV seropositivity\n* Immunocompromised subjects\n* Evidence of concurrent cervical adenocarcinoma in situ\n* Concurrent malignancy except for nonmelanoma skin lesions, because treatment for other cancers have systemic effects","100 Years",{"count":569,"type":21},78,[57],"This is a phase II double blind, placebo-controlled, randomized study of Artesunate vaginal inserts for the treatment of women who have cervical high grade intraepithelial neoplasia (CIN2\u002F3).",[573,27,574,575,576],"CIN 2\u002F3","Pre-Cancerous Dysplasia","Cervical Dysplasia","HPV Related Disease",[578,579,580,581,109,582,583,584,585,586,324,587],"treatment study","cancer prevention","non-surgical","HPV related disease","topical treatment","vaginal inserts","artesunate","artemisinin","non-invasive","vaginal suppository","2025-09-29",{"date":550,"type":37},{"date":591,"type":37},"2020-09-09",{"date":240,"type":21},{"name":594,"class":213},"Frantz Viral Therapeutics, LLC",7,{"id":597,"slug":598,"hasResults":12,"nctId":599,"briefTitle":600,"officialTitle":601,"acronym":602,"eligibilityCriteria":603,"healthyVolunteers":12,"sex":604,"minAge":53,"maxAge":605,"enrollmentInfo":606,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":608,"conditions":609,"keywords":612,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":614,"lastUpdatePostDateStruct":615,"startDateStruct":617,"completionDateStruct":619,"leadSponsor":620,"locationsCount":45},"100509309","prevalence-and-clinical-implications-of-hpv-infection-in-male-ibd-patients-100509309","NCT05911750","Prevalence and Clinical Implications of HPV Infection in Male IBD Patients","Prevalence and Clinical Implications of Human Papillomavirus Infection in the Male Population With Inflammatory Bowel Disease","PAPIMALE","Inclusion Criteria:\n\n* Diagnosed Crohn's disease or ulcerative colitis (at least 3 months before enrollment)\n* Male\n* Age from 18 to 79 years\n\nExclusion Criteria:\n\n* Unclassified Inflammatory Bowel Disease\n* Diarrhea (\\> 3 bowel movements\u002Fday) with rectal bleeding at enrollment\n* Prior full proctectomy\n* Inability to collect the biological samples\n* Inability to complete the questionnaire\n* Refusal to sign the informed consent","MALE","79 Years",{"count":607,"type":21},384,"The study aims at describing the prevalence of Human Papillomavirus (HPV) infection in anal and oral samples of men with Inflammatory Bowel Disease (IBD) and detecting risk factors for the infection.",[27,610,611],"Dysplasia Anus","Oral Cavity Disease",[613],"HPV, oral swab, anal swab","2025-09-08",{"date":616,"type":37},"2025-09-12",{"date":618,"type":37},"2023-02-12",{"date":118,"type":21},{"name":621,"class":44},"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau",{"id":623,"slug":624,"hasResults":12,"nctId":625,"briefTitle":626,"officialTitle":627,"acronym":628,"eligibilityCriteria":629,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":630,"targetDuration":4,"studyType":22,"phases":632,"briefSummary":633,"conditions":634,"keywords":645,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":651,"lastUpdatePostDateStruct":652,"startDateStruct":654,"completionDateStruct":656,"leadSponsor":658,"locationsCount":659},"100521874","phase-2-phase-ii-study-of-artesunate-ointment-for-the-treatment-of-vulvar-high-grade-squamous-intraepithelial-lesions-vulvar-hsil-vin23-100521874","NCT06075264","Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2\u002F3)","A Phase II Double-blind, Placebo-controlled, Randomized Trial of Topical Artesunate Ointment for the Treatment of Patients With Vulvar High-grade Squamous Intraepithelial Lesions (Vulvar HSIL)","ART-VIN IIB","Inclusion Criteria:\n\n* Adult women age ≥ 18 years\n* Capable of informed consent\n* Able to collaborate with planned follow-up (transportation, compliance history, etc)\n* Biopsy diagnosis of high-grade vulvar dysplasia (VIN2, VIN3, VIN2\u002F3, HSIL), including both new and recurrent disease. A biopsy diagnosis of vulvar high-grade squamous intraepithelial lesion within the previous 3 months which was not excised or otherwise treated may be accepted for study entry.\n* Positive HPV test at study entry (any genotype).\n* Women of childbearing potential agree to use birth control during the dosing phase (through week 8).\n* Laboratory values at Screening of:\n\n  * Serum alanine transaminase (SGPT\u002FALT) \\\u003C 5 x upper limit of normal (ULN)\n  * Serum aspartate transaminase (SGOT\u002FAST) \\\u003C 5 x ULN\n  * Serum Bilirubin (total) \\\u003C 2.5 x ULN\n  * Serum Creatinine ≤ 1.5 x ULN\n* Weight ≥ 50kg\n\nExclusion Criteria:\n\n* Pregnant and nursing women\n* Concurrent anal, vulvar, or cervical cancer\n* HIV-positive participants with a CD4 count \\\u003C 200\n* Participants infected with HIV-1 if not on a stable, suppressive antiretroviral therapy (ART) regimen.\n* Unwillingness to undergo an excisional procedure at week 18 to either remove HSIL lesions, or to document histologic regression at a site where HSIL was present at study entry.\n* Currently receiving systemic chemotherapy or radiation therapy for another cancer.\n* Concomitant use of Efavirenz for HIV antiretroviral treatment\n* Concomitant use of strong UGT inhibitors\n* Concomitant use of imiquimod, cidofovir, or 5-fluorouracil (5-FU) for the duration of the study\n* Concurrent dermatological conditions affecting the vulva (e.g., herpetic lesion, Crohn's disease, hidradenitis suppurativa) or vulvar dermatoses (e.g., lichen sclerosis or planus, atopic dermatitis, genital atrophy).\n* Concurrent treatment with systemic corticosteroids",{"count":631,"type":21},27,[57],"This is a phase II double-blind, placebo-controlled study of artesunate ointment for the treatment of HPV-associated vulvar HSIL (usual type vulvar intraepithelial neoplasia 2\u002F3).",[635,27,636,574,29,637,638,639,640,641,642,643,644],"Vulvar Diseases","Vulvar HSIL","VIN, Usual Type","VIN 2 of Usual Type","VIN 3 of Usual Type","Vin II","Vin III","VIN Grade 2","VIN Grade 3","High Grade Intraepithelial Neoplasia",[582,646,580,647,648,190,309,649,650],"ointment","vulvar cancer prevention","high-risk HPV","vulvar HSIL","High grade lesions","2025-08-13",{"date":653,"type":37},"2025-08-14",{"date":655,"type":37},"2023-12-06",{"date":657,"type":21},"2027-12",{"name":594,"class":213},5,{"id":661,"slug":662,"hasResults":12,"nctId":663,"briefTitle":664,"officialTitle":665,"acronym":4,"eligibilityCriteria":666,"healthyVolunteers":12,"sex":423,"minAge":667,"maxAge":4,"enrollmentInfo":668,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":670,"conditions":671,"keywords":673,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":675,"lastUpdatePostDateStruct":676,"startDateStruct":678,"completionDateStruct":680,"leadSponsor":681,"locationsCount":45},"100599642","feasibility-of-hpv-testing-with-mail-delivered-sample-collection-kits-100599642","NCT07087145","Feasibility of HPV Testing With Mail-delivered Sample Collection Kits","Persistent Oral HPV Among Diverse PLWH: A Pilot Study to Evaluate the Feasibility and Acceptability of Testing for Oral HPV DNA Infection With Mail-delivered Sample Collection Kits","Inclusion Criteria:\n\n1. Over 35 years of age\n2. Member of a sexual or gender group considered sexual minority men (men who have sex with men, trans-women)\n3. Person living with HIV\n4. Willing and able to receive a package through United States (US) postal service\n5. Willing and able to return a package through FedEx\n6. Able to attend a clinic visit at University of California, San Francisco (UCSF) Mt. Zion campus\n\nExclusion Criteria:\n\n* Does not meet the above criteria","35 Years",{"count":669,"type":21},135,"People living with human immunodeficiency virus (PLWH) have an estimated 1.6-6.0 times increased risk of developing oropharyngeal cancer (OPC) compared with individuals in the general population. 70% of OPCs are caused by human papillomavirus (HPV), and PLWH also have an increased prevalence of oral HPV infection. Disparities by race\u002Fethnicity also include a later stage of diagnosis and less frequent cancer-directed treatment for members of ethnic minority groups. There is little known regarding the racial\u002Fethnic differences in oral HPV infection, persistence of oral HPV infection, or progression of oral HPV infection to OPC among PLWH. This is an observational, prospective cohort study to investigate the feasibility of alternative sample collection methods for HPV testing among PLWH.",[27,104,672],"HPV-Related Malignancy",[674],"HPV Testing","2025-07-29",{"date":677,"type":37},"2025-08-01",{"date":679,"type":37},"2024-11-17",{"date":240,"type":21},{"name":682,"class":44},"University of California, San Francisco",{"id":684,"slug":685,"hasResults":12,"nctId":686,"briefTitle":687,"officialTitle":687,"acronym":4,"eligibilityCriteria":688,"healthyVolunteers":222,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":689,"targetDuration":4,"studyType":22,"phases":691,"briefSummary":692,"conditions":693,"keywords":694,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":697,"lastUpdatePostDateStruct":698,"startDateStruct":700,"completionDateStruct":702,"leadSponsor":704,"locationsCount":45},"100560203","determining-the-frequency-of-occurrence-and-defining-the-most-appropriate-screening-test-for-anal-intraepithelial-neoplasia-ain-in-patients-with-human-papillomavirus-hpv-related-gynecological-diseases-100560203","NCT06574087","Determining the Frequency of Occurrence and Defining the Most Appropriate Screening Test for Anal Intraepithelial Neoplasia (AIN) in Patients With Human Papillomavirus (HPV) Related Gynecological Diseases.","Inclusion Criteria:\n\n* HPV related gynecological disease confirmed in histo-pathological examination\n* the posibility to obtain material from gynecological organ and from anal canal",{"count":690,"type":21},248,[24],"The primary aim of the study is to determine the total risk of AIN in group of HPV-RGD survivors and additionally to establish an exact risk for each of HPV-related gynecological precancers\u002Fcancers. Moreover, the most appropriate screening test for HSIL(AIN) in this group of patients will be determined. It will be effectuated by performing two kinds of tests: hrHPV test for the 14 most common oncogenic HPV types and the liquid cytology from both the lower genital tract and anal canal with subsequent high resolution anoscopy (HRA) with potential biopsy\u002Fexcision of suspected lesions and histopathological examination.",[352,27],[695,309,696],"anal cancer","anal intraepithelial neoplasia","2025-07-18",{"date":699,"type":37},"2025-07-23",{"date":701,"type":37},"2023-01-13",{"date":703,"type":21},"2027-01",{"name":705,"class":44},"PCK Marine Hospital in Gdynia"]